Medical Advocates
Efavirenz (Sustiva/Strocrin)
 
Journal Citations:
Treatment Strategies

Dosage Adjustment
 Simplification Therapy
 Intensification Therapy
 Treatment Interruption
 Hepatic Disease
 Renal Disease
Metabolic Disorders
 HIV/HCV Coinfection
 HIV/TB Coinfection

 
Efavirenz Adult Treatment Main New/Newsworthy Home Page      
Last Update:  December 11, 2008
  Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader
Dosage Adjustment
 
 
Successful efavirenz dose reduction in HIV type 1-infected individuals with cytochrome
P450 2B6 *6 and *26.
 Gatanaga H, Hayashida T, Tsuchiya K, et al  
 Clin Infect Dis. 2007 Nov 1;45(9):1230-7.
Abstract

A WEEK-IN-REVIEW FEATURED REPORT
Outcomes of dosage adjustments used to manage antiretroviral drug interactions.
 Park-Wyllie LY, Levine MA, Holbrook A, et al
Clin Infect Dis. 2007 Oct 1;45(7):933-
Abstract  
Simplification Therapy
 
  Genotypic and phenotypic resistance patterns at virological failure in a simplification trial with
nevirapine, efavirenz or abacavir.
 de Echaguen AO, Arnedo M, Xercavins M, et al
AIDS. 2005 Sep 2;19(13):1385-1391.
Abstract
Intensification Therapy
 
  A WEEK-IN-REVIEW FEATURED REPORT
Intensification of a triple-nucleoside regimen with tenofovir or efavirenz in HIV-1-infected
patients with virological suppression.
Gulick RM, Lalama CM, Ribaudo HJ, et al
AIDS. 2007 Apr 23;21(7):813-823.
Abstract
Treatment Interruption
 
 
Variability in the plasma concentration of efavirenz and nevirapine is associated with genotypic
resistance after treatment interruption.
 Darwich L, Esteve A, Ruiz L, et al
Antivir Ther. 2008;13(7):945-51.
 Abstract
Hepatic Disease
 
  Efavirenz-therapy in HIV-patients with Underlying Liver Disease: Importance of Continuous TDM
of EFV.
Katsounas A, Frank A, Klinker H, Langmann P.
 Eur J Med Res. 2007 Aug 16;12(8):331-6
 Abstract
Renal Disease
 
  Experience with efavirenz in end-stage renal disease.
Prime KP, Woolfson RG, Pakianathan MR
 Int J STD AIDS. 2003 Jul;14(7):497-8.
 Abstract
Metabolic Disorders
 
 
The role of efavirenz compared with protease inhibitors in the body fat changes associated with highly active
antiretroviral therapy.
 Pérez-Molina JA, Domingo P, Martínez E, Moreno S.
J Antimicrob Chemother. 2008 May 14
 Abstract

Long-term and concentration-dependent beneficial effect of efavirenz on HDL-cholesterol in
HIV-infected patients.
 Pereira SA, Branco T, Corte-Real RM,
 Br J Clin Pharmacol. 2006 May;61(5):601-4
 Abstract

Substitution of nevirapine or efavirenz for protease inhibitor versus lipid-lowering therapy for the
management of dyslipidaemia.
 Calza L, Manfredi R, Colangeli V, et al 
AIDS. 2005 Jul 1;19(10):1051-8. R
 Abstract
HIV/HCV Coinfection
 
 
Effect of Treatment With Efavirenz on Neuropsychiatric Adverse Events of Interferon in HIV/HCV-
Coinfected Patients.
 Quereda C, Corral I, Moreno A, Pérez-Elías MJ,
 J Acquir Immune Defic Syndr. 2008 Jul 23.
Abstract
HIV/Tuberculosis Coinfection
 
 
Pharmacokinetics of Efavirenz When Co-administered With Rifampin in TB/HIV Co-infected Patients:
Pharmacogenetic Effect of CYP2B6 Variation.
 Kwara A, Lartey M, Sagoe KW, et al  
J Clin Pharmacol. 2008 Sep;48(9):1032-40.
 Abstract
 
Administration of efavirenz (600 mg/day) with rifampicin results in highly variable levels
but excellent clinical outcomes in patients treated for tuberculosis and HIV.
 Friedland G, Khoo S, Jack C, Lalloo U.  
J Antimicrob Chemother. 2006 Oct 10;
Abstract

Efavirenz trough levels are not associated with virological failure throughout therapy
with 800 mg daily and a rifampicin-containing antituberculosis regimen.
Lopez-Cortes LF, Ruiz-Valderas R, Ruiz-Morales J, et al
J Antimicrob Chemother. 2006 Sep 6;
 Abstract
 

Efavirenz Adult Treatment Main New/Newsworthy Home Page      

Efavirenz Journal Citations: Adult/Adolescent Treatment